MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Viridian Therapeutics Total Liabilities 2011-2026 | VRDN
Annual Total Liabilities Viridian Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 M | 70.8 M | 48.4 M | 40 M | 16 M | 11.2 M | 14.5 M | 14.8 M | 14 M | 4.58 M | 2.49 M | 2.1 M | 1.65 M | 24.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | 1.65 M | 31.6 M |
Quarterly Total Liabilities Viridian Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.2 M | 67.2 M | 56.5 M | 70.8 M | 64.4 M | 56.3 M | 47.9 M | 48.4 M | 45.2 M | 35.6 M | 36.1 M | 40 M | 31.6 M | 27.9 M | 16.5 M | 16 M | 16.6 M | 19.3 M | 16.8 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 14 M | 14 M | 14 M | 14 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 74.2 M | 9.7 M | 26.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
4.9 M | $ 0.9 | 0.78 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.6 | 1.35 % | $ 3.75 B | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
11.1 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Fennec Pharmaceuticals
FENC
|
35.1 M | $ 6.78 | -1.02 % | $ 194 M | USA |
 |
ChromaDex Corporation
CDXC
|
29.9 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
Galectin Therapeutics
GALT
|
146 M | $ 2.34 | -1.48 % | $ 150 M | USA |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Genmab A/S
GMAB
|
2.02 B | $ 26.37 | -1.01 % | $ 16.5 B |  Danmark |
 |
BioNTech SE
BNTX
|
2.76 B | $ 101.6 | -0.45 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.1 | - | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 23.28 | -0.6 % | $ 2.96 B | USA |
 |
Heron Therapeutics
HRTX
|
242 M | $ 1.23 | 3.39 % | $ 205 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
ImmuCell Corporation
ICCC
|
15.5 M | $ 8.27 | 0.24 % | $ 74.6 M | USA |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.9 | -0.64 % | $ 4.77 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
151 M | $ 1.42 | 1.31 % | $ 235 M | France |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
226 M | $ 5.05 | -1.66 % | $ 138 M | France |